Drugs / OVM-200
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05104515 | Nov 2021 → Nov 2025 overdue | non-small cell lung carcinoma, ovarian cancer, prostate cancer | Oxford Vacmedix UK Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-05-22 | Oxford Vacmedix UK Ltd. | Results OVM-200 Phase 1 clinical trial accepted for presentation at ASCO oxfordvacmedix.com ↗
The results show: Excellent Safety Profile (primary endpoint): OVM-200 is very well tolerated with no serious adverse drug reactions or no dose-limiting toxicities. |
| 2026-04-22 | Oxford Vacmedix UK Ltd. | Results Oxford Vacmedix announce results of successful Phase 1 trial of OVM-200 oxfordvacmedix.com ↗
The OVM-200 Phase 1 trial has met both primary and secondary endpoints and additionally early observations of clinical efficacy have been seen. |
| 2026-01-15 | Oxford Vacmedix UK Ltd. | Results Publication of OVM-200 Phase 1a results in Lancet group journal oxfordvacmedix.com ↗ |
| 2025-02-20 | Oxford Vacmedix UK Ltd. | Regulatory First patient treated with new extended dosing of OVM-200 cancer vaccine oxfordvacmedix.com ↗
The extended dosing protocol was first suggested by the clinical investigators in the trial, following the excellent safety record seen in Phase 1a. |
| 2023-10-10 | Oxford Vacmedix UK Ltd. | Results New publication highlights importance of survivin as target and potential for combination use to treat cancer oxfordvacmedix.com ↗
A new publication in Advanced Therapeutics comprehensively reviews the rationale and preclinical results for OVM-200 both alone and in combination. |
| 2021-08-10 | Oxford Vacmedix UK Ltd. | Regulatory MHRA approval for Phase 1 trial of lead cancer vaccine OVM-200 oxfordvacmedix.com ↗
Oxford Vacmedix, the UK-based biopharma company focused on the development of cancer vaccines announced today that approval for a Phase 1 trial of OVM-200 has been received from the MHRA (Medicines and Healthcare products Regulatory Authority). |
All press releases naming this drug 18 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OVM-200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05104515 ↗ |
| Modality | Vaccine | “OVM-200, a survivin recombinant overlapping peptide (ROP) vaccine” PMID 41536940 ↗ Dec 2025 |
| Route | Subcutaneous | “Twelve eligible patients received three subcutaneous OVM-200 doses at 2-week intervals using a 3 + 3 dose-escalation design.” PMID 41536940 ↗ Dec 2025 |